NEW YORK, Aug. 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of SeaStar Medical Holding Corporation (NASDAQ: ICU). Shareholders who purchased shares of ICU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/seastar-medical-loss-submission-form/?id=97701&from=4 CLASS PERIOD: ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In SeaStar To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 investing in SeaStar stock or options between October 31, 2022 and March 26, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YO ...

Core Viewpoint - A class action securities lawsuit has been filed against SeaStar Medical Holding Corporation, alleging securities fraud that affected investors between October 31, 2022, and March 26, 2024 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that SeaStar Medical and Legacy SeaStar had inadequate compliance controls related to the Humanitarian Device Exemption (HDE) Application [2]. - It is alleged that the FDA was unlikely to approve the HDE Application in its current form, and the regulatory prospects of the selective cytopheretic device were overstated [2]. - The company is accused of downplaying the severity of deficiencies in its financial controls while overstating efforts to remediate these issues [2]. - SeaStar allegedly failed to properly account for the classification of certain outstanding warrants and a prepaid forward agreement [2]. - The lawsuit suggests that SeaStar may need to restate one or more previously issued financial statements [2]. - As a result of these issues, the company's public statements were claimed to be materially false and misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the relevant time frame have until September 6, 2024, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing significant compensation for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of SeaStar Medical Holding Corporation (NASDAQ: ICU). Shareholders who purchased shares of ICU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/seastar-medical-loss-submission-form/?id=96740&from=3 CLASS PERI ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In SeaStar To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 investing in SeaStar stock or options between October 31, 2022 and March 26, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YO ...

NEW YORK, Aug. 19, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of SeaStar Medical Holding Corporation (NASDAQ: ICU). Shareholders who purchased shares of ICU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/seastar-medical-loss-submission-form/?id=96029&from=4 CLASS PERIOD: ...

Core Viewpoint - The Rosen Law Firm is reminding investors who purchased SeaStar Medical Holding Corporation securities during the specified class period of the upcoming lead plaintiff deadline on September 6, 2024, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought SeaStar securities between October 31, 2022, and March 26, 2024, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the September 6, 2024 deadline [3][6]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against SeaStar - The lawsuit alleges that SeaStar and/or Legacy SeaStar made false or misleading statements regarding their compliance controls and procedures related to the HDE Application [5]. - It is claimed that the FDA was unlikely to approve the HDE Application in its current form, and the company's regulatory prospects were overstated [5]. - The lawsuit also states that SeaStar downplayed deficiencies in its financial controls and overstated efforts to remediate these issues, leading to potential restatements of previously issued financial statements [5].

NEW YORK, Aug. 15, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of SeaStar Medical Holding Corporation (NASDAQ: ICU). Shareholders who purchased shares of ICU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/seastar-medical-loss-submission-form/?id=95565&from=4 CLASS PERIOD: ...

DENVER, Aug. 13, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) ("SeaStar Medical" or the "Company"), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three and six months ended June 30, 2024 and provides a business update. "Our recent commercial, clinical and corporate achievements have significantly strengthened our company and support an active and excit ...

Core Viewpoint - SeaStar Medical Holding Corporation (NASDAQ: ICU) is facing allegations of issuing materially false and misleading statements regarding its compliance controls and financial reporting, which may lead to a restatement of financial statements and an overstatement of its business prospects [2]. Group 1 - The class period for the allegations is from October 31, 2022, to March 26, 2024 [2]. - Allegations include deficiencies in compliance controls related to the Humanitarian Device Exemption (HDE) Application and the likelihood of FDA disapproval of the application in its current form [2]. - The company is accused of downplaying the severity of deficiencies in its financial controls and overstating efforts to remediate these issues [2]. Group 2 - SeaStar is likely to restate one or more previously issued financial statements due to improper accounting for certain outstanding warrants and a prepaid forward agreement [2]. - The company's public statements regarding its post-merger business and financial prospects are claimed to be materially false and misleading [2]. - Shareholders are encouraged to register for the class action by September 6, 2024, to monitor the case's progress [3].